Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo
Loading...
Download
Associated Records
Authors
File Licence
Editors
Date
2018-12-01
Source Title
Scientific Reports
Journal Title
Journal ISSN
Volume Title
Publisher
Springer Science and Business Media LLC
Melbourne Authors
Affiliation
Surgery (Austin & Northern Health)
Document Type
Journal Article
Subject Code
Citation
Stevenson, A. J., Ager, E. I., Proctor, M. A., Škalamera, D., Heaton, A., Brown, D. & Gabrielli, B. G. (2018). Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo. Scientific Reports, 8 (1), pp.5144-. https://doi.org/10.1038/s41598-018-22882-w.
Access Status
Open Access
Access URL
Open Access URL
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
Successive rounds of chemical modification in three generations of benzopyran molecules have shown to select for different mechanisms of actions and progressive increases in anti-cancer activity. In this study, we investigated the mechanism of action of the third-generation benzopyran compounds, TRX-E-002-1 and TRX-E-009-1. High-content screening of a panel of 240 cancer cell lines treated with TRX-E-009-1 demonstrated it has broad anti-cancer potential. Within this screen, melanoma cell lines showed a range of sensitivities and subsequently a second independent panel of 21 melanoma 3D spheroid lines were assessed for their responses to both TRX-E-002-1 and TRX-E-009-1 compounds. Time-lapse microscopy illustrated both of these compounds caused mitotic delays in treated cells, resulting in either mitotic slippage or apoptosis. This finding along with immunostaining, in vitro polymerization assays, and animal experiments in both athymic and immunocompetent mice, demonstrates that these third-generation benzopyran compounds are potent tubulin polymerization inhibitors in vitro and in vivo, and this is the molecular basis of their anti-cancer activity in melanoma. These findings indicate these BP compounds may offer a novel anti-microtubule strategy for cancer intervention and provides the basis for further investigation into biomarkers of clinical sensitivity.